Eli Lilly (LLY) stock climbs on gross margin beat, raised 2024 revenue outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Eli Lilly (LLY) PT Raised to $1,001 at BMO Capital
April 30, 2024 4:50 PM EDTBMO Capital analyst Evan David Seigerman raised the price target on Eli Lilly (NYSE: LLY) to $1,001.00 (from $900.00) while maintaining a Outperform rating.
The analyst comments "A high-quality earnings miss is one that 1) characterizes unprecedented demand; 2) justifies performance miss with supply constraints; 3) highlights efforts... More
Eli Lilly (LLY) PT Raised to $885 at Cantor Fitzgerald
April 30, 2024 2:01 PM EDTCantor Fitzgerald analyst Louise Chen raised the price target on Eli Lilly (NYSE: LLY) to $885.00 (from $815.00) while maintaining a Overweight rating.
The analyst comments "For 1Q24, US Zepbound revenue was $517MM vs. $363MM for FactSet. Zepbound is already annualizing at over... More
Weight-loss drug drives Eli Lilly to raise 2024 sales forecast by $2 billion
April 30, 2024 6:50 AM EDTBy Bhanvi Satija and Patrick Wingrove
(Reuters) -Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday, lifting its shares nearly 5%.
Lilly said it expects significant production increases in the second half of the year for its obesity treatment and related diabetes drug Mounjaro, for which most doses are in shortage due to high demand.
Skyrocketing demand for Mounjaro and Zepbound, both chemically known as tirzepatide, has propelled the Indianapolis-based drugmaker's market value above $700 billion - surpassing that of Tesla and Walmart.
... MoreEli Lilly & Co. (LLY) Tops Q1 EPS by 10c; Raises guidance
April 30, 2024 6:48 AM EDTEli Lilly & Co. (NYSE: LLY) reported Q1 EPS of $2.58, $0.10 better than the analyst estimate of $2.48. Revenue for the quarter came in at $8.77 billion versus the consensus estimate of $8.94 billion.
GUIDANCE:
Eli Lilly & Co. sees FY2024 EPS of $13.50-$14.00, versus the... More
